Pioglitazone safe and effective for treating T2DM in patients with NASH

被引：0
|
作者：
Tim Geach
机构：
来源：
Nature Reviews Endocrinology | 2016年 / 12卷 / 9期
关键词：
D O I：
10.1038/nrendo.2016.113
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：498 / 498
相关论文
共 50 条
  • [1] Safety and Efficacy of Long-Term Pioglitazone Treatment for Patients With Prediabetes or T2DM and NASH
    Cusi, Kenneth
    Orsak, Beverly
    Lomonaco, Romina
    Finch, Joan
    Ortiz-Lopez, Carolina
    Bril, Fernando
    Diaz, Norma
    Kaminski-Graham, Rose
    Darland, Celia
    Musi, Nicolas
    Webb, Amy
    Hardies, Jean
    Tio, Fermin
    DIABETES, 2013, 62 : A309 - A309
  • [2] Predictors of response after extended pioglitazone treatment in patients with prediabetes or T2DM and nonalcoholic steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Hecht, Joan
    Ortiz-Lopez, Carolina
    Hardies, Jean
    Tio, Fermin
    Cusi, Kenneth
    HEPATOLOGY, 2013, 58 : 513A - 514A
  • [3] Statins: liver safety in patients with NASH, T2DM
    Reactions Weekly, 2017, 1656 (1) : 13 - 13
  • [4] Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
    Abdul-Ghani, Muhammad
    Jayyous, Amin
    Asaad, Nidal
    Helmy, Sherif
    Al-Suwaidi, Jassim
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (10)
  • [5] Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM
    Perez, Alfonso
    Zhao, Zhen
    Jacks, Randal
    Spanheimer, Robert
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2915 - 2923
  • [6] Is Treatment of Nonalcoholic Steatohepatitis with Pioglitazone Equally Effective in Patients with Prediabetes Compared with Type 2 Diabetes (T2DM)?
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Hecht, Joan
    Tio, Fermin
    Cusi, Kenneth
    DIABETES, 2017, 66 : A64 - A64
  • [7] Metabolic Predictors of Response to Pioglitazone Treatment in Patients with Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH)
    Bril, Fernando
    Sanchez, Paola Portillo
    Maximos, Maryann
    Lomonaco, Romina
    Orsak, Beverly
    Hecht, Joan
    Kalavalapalli, Srilaxmi
    Cusi, Kenneth
    DIABETES, 2015, 64 : A337 - A337
  • [8] Pioglitazone: no increased risk of bladder cancer with T2DM
    Reactions Weekly, 2017, 1668 (1) : 10 - 10
  • [9] Dapagliflozin Is Safe and Well Tolerated in Older Patients with T2DM
    Mansfield, Traci
    Fioretto, Paola
    Ptaszynska, Agata
    Yavin, Yshai
    Apanovitch, Anne Marie
    Johnsson, Eva
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2014, 63 : A71 - A71
  • [10] Adipose-tissue insulin resistance is a major metabolic abnormality of patients with IGT/T2DM and NASH: Reversal with pioglitazone treatment
    Gastaldelli, A.
    Hardies, J.
    Belfort, R.
    Harrison, S.
    Balas, B.
    Defronzo, R. A.
    Brown, K.
    Schenker, S.
    Cusi, K.
    DIABETES, 2007, 56 : A40 - A40
12345